Results 131 to 140 of about 22,142 (188)

Expired Ibrutinib as a Sustainable Corrosion Inhibitor for P110 Carbon Steel in Hydrochloric Acid: Integrated Experimental, Electrochemical, and Multiscale Computational Insights. [PDF]

Molecules
Alrafai HA, Ali IH, Bedair MA.
europepmc   +1 more source

Allogeneic Stem Cell Transplantation-A Salvage Option for High-Risk Chronic Lymphocytic Leukemia Patients: A 15-Year Single-Center Experience. [PDF]

Hematol Oncol
Mikhailova NB, Kislova MI, Ivanova MO, Zhuravleva JA, Dmitrieva EA, Kondakova EV, Smirnova AG, Krylova YV, Kudyasheva OV, Vlasova YY, Beynarovich AV, Volkov NP, Moiseev IS, Nikitin EA, Kulagin AD.   +14 more
europepmc   +1 more source

Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia. [PDF]

Blood Cancer J
Martindale SP, Azevedo RS, Harrison DA, Tesar B, Nguy W, Stiegler M, Ferre V, Rai V, Ren Y, Zhou Y, Tyekucheva S, Fernandes SM, Machado JH, Kandathilparambil Sasi B, Naeem A, Ott CJ, Brown JR.   +16 more
europepmc   +1 more source

Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies. [PDF]

Rev Cardiovasc Med
Gan H, Lin J, Sun Q, Xu J, He Q, Chen S, Feng Y, Hu B, Wang W.   +8 more
europepmc   +1 more source

Correction: Cost-effectiveness analysis of ibrutinib plus venetoclax for relapsed or refractory mantle cell lymphoma in China and the United States. [PDF]

Front Public Health
He J, Liu X, Yang Q.
europepmc   +1 more source

Pirtobrutinib Monotherapy for First-Line Chronic Lymphocytic Leukemia: A Non-Anchored Indirect Comparison Using Reconstructed Patient-Level Data. [PDF]

Hematol Rep
Messori A, Gasperoni L, Del Bono L, Damuzzo V.   +3 more
europepmc   +1 more source

Corrigendum to "Disappearance of the Defining Organized Ultrastructural Lesion in Chronic Lymphocytic Leukemia-Associated Monoclonal Immunotactoid Glomerulopathy After Ibrutinib Therapy" [<i>Kidney International Reports</i> Volume 11, Issue 8, August 2026, 106643]. [PDF]

Kidney Int Rep
Shibuki S, Yoshihara M, Fukuda M, Nawata A, Katsuya H, Kang D, Kawanishi K, Ogawa Y, Aoki S, Kimura S, Miyazono M.   +10 more
europepmc   +1 more source

DLBCL-microenvironment interactions: cytokine profiling and ECM-mediated ibrutinib resistance in a 3D bone-based model. [PDF]

Med Oncol
Ceccato J, Piazza M, Gualtiero G, Carraro S, Cinetto F, Biz C, Manni S, Pizzi M, Pianalto S, Zoletto S, Carabotta V, Danesin N, Ruggieri P, Dei Tos AP, Piazza F, Trentin L, Vianello F.   +16 more
europepmc   +1 more source

Where next for BTKi-BCL2i combinations in mantle cell lymphoma? [PDF]

Br J Haematol
Eyre TA.
europepmc   +1 more source